房前屋后"致富花" 豫南大别山北麓固始菊开乡间 小小野菊花何以成为乡村经济发展的"致富花"？其背后离不开科技赋能产业、种苗持续优化和订单市场 稳定。 漫步段集镇乐道冲村的乡间小路上，青山坡地、房前屋后的野菊花迎风摇曳，村民们挎着竹篓收割、骑 着三轮车转运，一派繁忙景象。路边收割的村民笑道，"这花好伺候，不用费啥劲，我们不出远门，在 房前屋后就能挣钱"！ 位于大别山北麓的固始县，气候温和湿润，土壤富含微量元素，适合野菊花生长。当地种植的野菊花一 次栽种可年收割两三茬，持续收益三至五年，具有易管理、抑杂草、价格稳等特点。2022年，信阳农林 学院驻乐道冲村工作队经多方调研后，决定引进药用野菊花试验种植项目。 图为村民采摘野菊花。舒志 摄 中新网郑州11月20日电 题：房前屋后"致富花" 豫南大别山北麓固始菊开乡间 作者 李海珠 "您这花品质好，按一块钱一斤最高价收购，行不？""好！" 初冬清晨，河南信阳固始县段集镇药用野菊花收储加工中心前，一辆辆满载野菊花的三轮车排着长队， 收购员戴昕宇和村民雷敏一问一答间，满是丰收的喜悦。 甫一走进收储加工中心，淡淡花香伴随着机器轰鸣声扑面而来。戴昕宇边忙活着收检野菊花边说，野 ...

Core Insights - The article highlights the successful cultivation of wild chrysanthemums in Wuwa Village, Pingdingshan City, Henan Province, which has become a significant source of income for local villagers and a key component of rural revitalization efforts [1] Company and Industry Summary - The wild chrysanthemum is described as both a beautiful landscape and a "wealth flower," serving as a health tea for villagers and a raw material for pharmaceutical companies [1] - The local youth, Wang Xihai, identified a business opportunity in wild chrysanthemum cultivation, partnering with China Resources Sanjiu Medical & Pharmaceutical Co., and successfully transitioned nearly 300 acres of land for this purpose with government support [1] - The wild chrysanthemum is known for its medicinal properties, particularly in traditional Chinese medicine, and its demand from pharmaceutical companies has been increasing year by year, with Wang's cultivation base expected to generate an annual income of no less than 300,000 yuan [1] - The integration of standardization and mechanization in the wild chrysanthemum industry has led to the development of a "dual chain" of medicinal and food uses, enhancing its market potential [1] - The current harvesting season has created a vibrant scene where villagers are busy collecting chrysanthemums while tourists enjoy the blooming flowers, illustrating a new picture of rural revitalization [1]

Core Viewpoint - The National Medical Products Administration (NMPA) announced that 28 batches of drugs produced by 17 companies do not meet regulatory standards, prompting investigations and corrective actions [3][5]. Group 1: Non-compliant Drugs - Five batches of fusidic acid cream produced by Aomei Pharmaceutical Factory failed due to particle size issues [3]. - Two batches of loratadine syrup from Want Pharmaceutical (Hainan) Co., Ltd. did not meet standards related to impurities [3]. - One batch of sodium phosphate oral solution from Shanghai Haihong Industrial Group's Chao Hu Jinchen Pharmaceutical Co., Ltd. failed due to relative density [3]. - Two batches of tocilizumab capsules from Shaanxi Xiyue Pharmaceutical Co., Ltd. did not meet dissolution rate standards [3]. - One batch of acetylcysteine effervescent tablets from Zhejiang Jinhua Kang'enbei Biopharmaceutical Co., Ltd. failed due to physical characteristics [3]. - Two batches of Twenty-five Flavor Coral Pills from Tibet Shenhui Pharmaceutical Co., Ltd. did not meet weight difference standards [3]. - Two batches of Qili San from Hubei Minkan Pharmaceutical Co., Ltd. failed due to content determination [3]. Group 2: Regulatory Actions - The NMPA has mandated that the involved companies take risk control measures such as suspending sales and conducting recalls [5]. - The NMPA requires provincial drug supervision departments to investigate potential illegal activities by the companies involved and to publicly disclose the results of these investigations [5].

Core Viewpoint - The National Medical Products Administration (NMPA) announced that 28 batches of drugs produced by 17 companies do not meet regulatory standards, highlighting quality control issues in the pharmaceutical industry [1][2][3]. Summary by Categories Non-compliance Details - Five batches of fusidic acid cream produced by Aumei Pharmaceutical are non-compliant due to particle size [1] - Two batches of loratadine syrup from Wante Pharmaceutical (Hainan) are non-compliant due to related substances [1] - One batch of sodium phosphate oral solution from Shanghai Haihong Industrial Group is non-compliant due to relative density [1] - Two batches of tosylate capsules from Shaanxi Xiyue Pharmaceutical are non-compliant due to dissolution rate [1] - One batch of acetylcysteine effervescent tablets from Zhejiang Jinhua Kang'enbei Biopharmaceutical is non-compliant due to physical properties [1] - Two batches of Twenty-five Flavor Coral Pills from Tibet Shenhou Pharmaceutical are non-compliant due to weight differences [1] Additional Non-compliance Findings - Two batches of Qili Powder from Hubei Minkan Pharmaceutical are non-compliant due to content measurement [2] - Four batches of Qingqi Huatan Pills from Hubei Ruihua Pharmaceutical are non-compliant due to dosage discrepancies [2] - Two batches of red peony from Sichuan Jinke Pharmaceutical and Sichuan Yixiangkang Pharmaceutical are non-compliant due to physical properties [2] - Three batches of red ginseng (red ginseng slices) from multiple companies are non-compliant due to identification issues and pesticide residue [2] - One batch of Gentian from Jiangsu Heshengtang Pharmaceutical is non-compliant due to impurities [2] - One batch of wild chrysanthemum from Jiangxi Xinjian Pharmaceutical is non-compliant due to content measurement [2] Regulatory Actions - The NMPA has mandated that the involved companies take risk control measures such as halting sales and conducting recalls [3] - Investigations into the causes of non-compliance are required, along with corrective actions [3] - Provincial drug supervision departments are instructed to investigate potential illegal activities by the companies involved [3] Public Awareness Initiatives - The NMPA has provided educational information regarding the significance of various non-compliance indicators, such as particle size, related substances, relative density, dissolution rate, physical properties, weight differences, content measurement, identification, pesticide residues, total reducing sugars, impurities, and moisture content [4][5]

Summary of Key Points Core Viewpoint - The National Medical Products Administration (NMPA) has announced that 28 batches of drugs produced by 17 companies do not meet regulatory standards, prompting investigations and corrective actions from the involved companies [1][3]. Group 1: Non-compliance Details - Five batches of fusidic acid cream produced by Aumei Pharmaceutical are non-compliant due to particle size issues [1] - Two batches of loratadine syrup from Wante Pharmaceutical (Hainan) are non-compliant due to related substances [1] - One batch of sodium phosphate oral solution from Shanghai Haihong Industrial Group is non-compliant due to relative density [1] - Two batches of tocilizumab capsules from Shaanxi Xiyue Pharmaceutical are non-compliant due to dissolution rate [1] - One batch of acetylcysteine effervescent tablets from Zhejiang Jinhua Kang'enbei Biopharmaceutical is non-compliant due to physical properties [1] - Two batches of Twenty-Five Flavor Coral Pills from Tibet Shenhui Pharmaceutical are non-compliant due to weight differences [1] Group 2: Additional Non-compliance Cases - Two batches of Qili Powder from Hubei Minkan Pharmaceutical are non-compliant due to content measurement [2] - Four batches of Qingqi Huatan Pills from Hubei Ruihua Pharmaceutical are non-compliant due to dosage discrepancies [2] - Two batches of red peony from Sichuan Jinke Pharmaceutical and Sichuan Yixiangkang Pharmaceutical are non-compliant due to physical properties [2] - Three batches of red ginseng (red ginseng slices) from multiple companies are non-compliant due to identification issues and pesticide residue [2] - One batch of Gentian from Jiangsu Heshengtang Pharmaceutical is non-compliant due to impurities [2] - One batch of wild chrysanthemum from Jiangxi Xinjian Pharmaceutical is non-compliant due to content measurement [2] Group 3: Regulatory Actions - The NMPA has mandated that the involved companies take risk control measures such as suspending sales and conducting recalls [3] - Investigations into the causes of non-compliance are required, along with corrective actions [3] - Provincial drug supervision departments are instructed to investigate potential illegal activities by the companies involved [3]

Core Viewpoint - The National Medical Products Administration (NMPA) announced that 28 batches of drugs produced by 17 companies do not meet regulatory standards, prompting investigations and corrective actions from the involved companies [1][3]. Summary by Categories Non-compliance Details - Five batches of fusidic acid cream produced by Aumei Pharmaceutical Factory failed due to particle size issues [1]. - Two batches of loratadine syrup from Wante Pharmaceutical (Hainan) Co., Ltd. did not meet standards due to related substances [1]. - One batch of sodium phosphate oral solution from Shanghai Haihong Industrial (Group) Co., Ltd. failed due to relative density [1]. - Two batches of tocilizumab capsules from Shaanxi Xiyue Pharmaceutical Co., Ltd. did not meet standards due to dissolution rate [1]. - One batch of acetylcysteine effervescent tablets from Zhejiang Jinhua Kang'enbei Biopharmaceutical Co., Ltd. failed due to physical properties [1]. - Two batches of Twenty-five Flavor Coral Pills from Tibet Shenhui Pharmaceutical Co., Ltd. did not meet standards due to weight differences [1]. Additional Non-compliance Cases - Two batches of Qili Powder from Hubei Minkan Pharmaceutical Co., Ltd. failed due to content determination [2]. - Four batches of Qingqi Huatan Pills from Hubei Ruihua Pharmaceutical Co., Ltd. did not meet standards due to dosage discrepancies [2]. - Two batches of red peony from Sichuan Jinke Pharmaceutical Co., Ltd. and Sichuan Yixiangkang Pharmaceutical Co., Ltd. failed due to physical properties [2]. - Three batches of red ginseng (red ginseng slices) from multiple companies failed due to identification issues and pesticide residue [2]. - One batch of Gentian from Jiangsu Heshengtang Pharmaceutical Co., Ltd. did not meet standards due to impurities [2]. - One batch of wild chrysanthemum from Jiangxi Xinjian Pharmaceutical Co., Ltd. failed due to content determination [2]. Regulatory Actions - The NMPA has mandated that the involved companies take risk control measures such as suspending sales and conducting recalls [3]. - Investigations into the causes of non-compliance are required, and the NMPA will pursue legal actions against any violations [3]. - The NMPA provided public education on the significance of various non-compliance indicators, including particle size, related substances, relative density, dissolution rate, physical properties, weight differences, content determination, identification, pesticide residues, total reducing sugars, impurities, and moisture content [3][4].

Group 1 - The article provides a skincare and mosquito prevention guide during the summer season, emphasizing the importance of protecting the skin from sun exposure and insect bites [1] - Traditional methods such as using herbal sachets and planting specific plants like mint and lavender are suggested for natural mosquito repellent [2] - The article highlights the timing of mosquito activity, recommending avoidance of outdoor activities during dawn and dusk, and suggests wearing protective clothing [2] Group 2 - For soothing mosquito bites, the article recommends using herbal remedies like mint and wild chrysanthemum, which can alleviate itching and reduce inflammation [3] - It also mentions the use of topical treatments such as calamine lotion and mild corticosteroids for more severe reactions [3] - The article advises against scratching the affected areas to prevent further irritation [3] Group 3 - The article suggests dietary adjustments to combat summer heat, recommending bitter foods like bitter lettuce and lotus leaf porridge to help regulate body temperature and reduce moisture [4] - It emphasizes the importance of hydration and consuming high-fiber foods to maintain overall health during the summer [4] - The article concludes that a proper diet can help reduce the body's attractiveness to mosquitoes, thereby minimizing bites [4]